Written question asked by Louise Ellman (Labour) on Wednesday, 20 March 2019, in the House of Commons. It was due for an answer on Friday, 22 March 2019. It was answered by Harriett Baldwin (Conservative) on Wednesday, 27 March 2019 on behalf of the Department for International Development.
Tuberculosis: Research
- Question
-
To ask the Secretary of State for International Development, what assessment she has made of the effectiveness of the UK's contribution to global TB research and role in advancing the further development of diagnostics, improved treatments and a TB vaccine; and if she will make a statement.
- Answer
-
The UK Government is a major investor in tuberculosis (TB) research, for the development of diagnostics, improved treatments and TB vaccines. The UK also supports applied health research, to strengthen health systems, to ensure effective delivery of health services so that new products, once available, can be used appropriately.
To date, DFID support has been instrumental in the development of five new diagnostics for TB, including GeneXpert, which is used routinely in the UK NHS, has reduced the time taken to diagnose drug-sensitive and drug resistant TB from several weeks to a few hours. DFID support also enabled the development of the first paediatric TB medicine, which is now available in 80 countries across the globe.
Secondary information
- Type
- Written question
- Reference
- 234697
- Session
- 2017-19
- Subjects
- Diagnosis Medical treatments Research Vaccination Tuberculosis
- Contains statistics
- Yes
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2019-03-27 14:27:23 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/234697
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/234697
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/234697